Veblocema (infliximab)

Region: 🇪🇺 EU
Active substance: infliximab
Company: Celltrion Healthcare Hungary Kft.
Status: Application withdrawn
Therapeutic area: Arthritis, Rheumatoid; Crohn Disease; Colitis, Ulcerative
Application: EMEA/H/C/006901
ATC: L04AB02
Official record: www.ema.europa.eu

Indication

Treatment of adults with Rheumatoid arthritis, Crohn’s disease or Ulcerative colitis

Regulatory milestones

Fri 08 May 2026🇪🇺 Application withdrawn (EU)

Veblocema (infliximab): EU application withdrawn

Celltrion Healthcare Hungary Kft. · source

Same substance in other markets

🇪🇺 Flixabi Authorised · Samsung Bioepis NL B.V.
🇪🇺 Remicade Authorised · Janssen Cilag International NV
🇪🇺 Inflectra Withdrawn · Pfizer Europe MA EEIG
🇪🇺 Remsima Authorised · Celltrion Healthcare Hungary Kft.
🇪🇺 Zessly Authorised · Sandoz GmbH
🇪🇺 ABP 710 Application withdrawn · Amgen Europe B.V.

Follow Veblocema

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.